S. Korea notes rise in rare, emerging diseases | Scotland increases support for patient access to new medicines | Changes could be coming to U.K.'s Cancer Drugs Fund
Web Version
 
October 9, 2014
SIGN UP|FORWARD|ARCHIVE|ADVERTISE
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science

Top Story
S. Korea notes rise in rare, emerging diseases
The Korea Centers for Disease Control and Prevention in South Korea noted that 112,850 people in the country contracted rare diseases in 2013, an increase of about 23% over 2012. Diseases included dengue infections, up 69% over last year, as well as Lyme disease, chikungunya, bacillary dysentery and melioidosis. The center attributed the increase to a rise in travel and imported foods. BioSpectrum Asia (10/7)
Share: LinkedInTwitterFacebookGoogle+Email
Europe
Scotland increases support for patient access to new medicines
Scotland will double its funding to improve patient access to new medicines, making more than $64 million available through the New Medicines Fund, which recently replaced the Rare Conditions Medicines Fund. The fund is financed by pharmaceutical industry rebates to the Scottish government established under the Pharmaceutical Price Regulation Scheme. The Association of the British Pharmaceutical Industry expressed its support for using Price Regulation Scheme payments to increase access. PharmaTimes (U.K.) (10/7)
Share: LinkedInTwitterFacebookGoogle+Email
Changes could be coming to U.K.'s Cancer Drugs Fund
NHS England is seeking input on three proposals that will change how the Cancer Drugs Fund operates. The group is considering an option for drugmakers to change prices so their products continue to be covered and a re-evaluation that would remove drugs with the least clinical benefit. PharmaTimes (U.K.) (10/5)
Share: LinkedInTwitterFacebookGoogle+Email
Asia Pacific
Asian orthobiologics market could hit $700M in 4 years, report says
A report from MicroMarketMonitor predicts that by 2018, the Asian orthobiologics market could be worth about $700 million, driven in large part by increased expenditures from the rising middle class and the aging population. The Asian market is dominated by Japan, which made up 40% of the market share this year. BeckersSpine.com (10/6)
Share: LinkedInTwitterFacebookGoogle+Email
North America
FDA approves emergency use of experimental drug to fight Ebola
The FDA has authorized Chimerix to provide physicians with brincidofovir to be used in patients with Ebola. Laboratory research suggests that the experimental oral antiviral drug may be effective against the virus. Fox Business/The Associated Press (10/6)
Share: LinkedInTwitterFacebookGoogle+Email
Costly specialty drugs offer value for the money, study finds
A study in the journal Health Affairs found that specialty drugs offer reasonable value because they tend to confer greater benefits despite having higher costs compared with traditional drugs. The health care industry is facing the challenge of making sure drugs are affordable without thwarting drugmakers' financial incentives to invest in research to develop innovative treatments, Jason Millman writes. The Washington Post (tiered subscription model)/Wonkblog (10/6)
Share: LinkedInTwitterFacebookGoogle+Email
Global
WHO releases guidance on use of blood transfusion against Ebola
An interim guidance on treating Ebola infection with blood transfusion has been issued by the World Health Organization. While blood collected from Ebola survivors has not been proven as effective, the treatment has been prioritized for further investigation. BeckersHospitalReview.com (10/7)
Share: LinkedInTwitterFacebookGoogle+Email
Merck Serono partners with U.K. groups to develop cancer drugs
Merck Serono has entered into a cancer-drug discovery and development deal with the Institute of Cancer Research and the Wellcome Trust in the U.K. The project will focus on Merck Serono and the institute's tankyrase inhibitor research programs. Merck Serono will get the rights to further develop the selected drug candidate when the collaboration ends. Genetic Engineering & Biotechnology News (10/7)
Share: LinkedInTwitterFacebookGoogle+Email
Report: Medtech market sales could reach $514B by 2020
An EvaluateMedTech report projects that the medical-device market could see $514 billion in sales over the next six years, with the in vitro diagnostics segment expected to account for the biggest sales growth. Meanwhile, worldwide research and development expenditures in the sector could hit $30.5 billion by 2020, according to the report presented at the 2014 AdvaMed conference being held this week. BeckersSpine.com (10/6)
Share: LinkedInTwitterFacebookGoogle+Email
Report pegs global patient monitoring market at $29.7B
The global market for patient monitoring systems is currently valued at $29.7 billion, a 7% increase from 2013, according to a Kalorama Information report. Bruce Carlson, Kalorama's publisher, attributes this growth in part to the transition to remote or wireless systems and the need to reduce the amount of time patients spend in the hospital. MobiHealthNews.com (10/7)
Share: LinkedInTwitterFacebookGoogle+Email
Featured Press Releases
 
DIA News
International Data Integrity Workshop
DIA
This two-day workshop will provide an opportunity to build awareness for regulatory agencies and industry regarding the importance of integrity in pharmaceutical science. Discussions will include the exploration of methods in collecting metrics to evaluate effectiveness and more! Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
 
DIA publications
DIA's publications provide an excellent opportunity to share your work with and receive feedback from our global, multidisciplinary educational network. Our Global Forum communicates information related to drug development and lifecycle management on a global basis, including regional and international industry and regulatory updates, plus updates from and about DIA educational and networking programs that are relevant to your professional experiences. Our peer-reviewed research journal Therapeutic Innovation & Regulatory Science publishes science-based articles on innovations in medical product development/discovery, the translation of new science into practical solutions for patients, plus commentaries, book reviews, guidelines and other article types. Learn more about publishing with DIA today! And remember: These DIA publications come as an exclusive benefit of DIA membership. Not yet a DIA member? Join DIA today!
Share: LinkedInTwitterFacebookGoogle+Email
SmartQuote
We adore chaos because we love to produce order."
-- M.C. Escher,
Dutch graphic artist
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about DIA ->About DIA | Meetings & Trainings | News & Publications | Membership
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Lisa Gough
Advertising:  Meryl Harold
  P: 202.407.7828
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information